BELLEVUE, Wash., August 18, 2023 — Viome Life Sciences announced the completion of its USD 86.5 million Series C investment round, which was oversubscribed. Viome Life Sciences is a company that transforms scientific discoveries into useful and individualized health solutions. Major investors include Bold Capital, WRG Ventures, Khosla Ventures, and other current and new investors. The additional funding, which increases Viome’s total to $175M, will support retail growth and R&D initiatives.
“Viome is leading a disruptive shift by leveraging the natural power of food and nutrition in a world where healthcare has frequently been reactive, treating symptoms and focusing on diseases only after they show. Our goal is to improve people’s quality of life so that they can thrive in health and vitality, according to Viome Founder and CEO Naveen Jain. “At Viome, we give our consumers the power of a personalised nutrition plan, cutting through the clutter of passing fads and generalized recommendations. With the help of our consumers and investors, we are on a mission to redefine aging itself. Building wellness pathways with one another can potentially improve the lives of billions of people worldwide.
In contrast to a one-size-fits-all diet, Viome’s innovative approach to health employs research to determine the best result for each customer based on their particular microbial and human gene expressions. The beginning and development of many chronic diseases are being facilitated by modern nutritional practices that fail to consider each individual’s biochemical diversity. Viome’s data-driven methodology is highly customized and doesn’t rely on general dietary recommendations that treat everyone equally. Viome has created at-home testing and custom-made health products using AI and cutting-edge algorithms to assess the world’s largest gene expression data set from over 600,000 samples. This allows each person to receive the specific nutrition their body requires.
“We strategically decided to invest in Viome after realizing how its ground-breaking RNA technology and cutting-edge AI could be combined. When combined with an unrivaled reservoir of biological data, this synergy not only portends a revolution but also ushers in a new age in healthcare. Robbie Schwietzer, Partner at Khosla Ventures, described the prospect as “astonishing: the very prevention of an epidemic wave of chronic diseases, spanning mental, metabolic, cognitive, and digestive health. Our cooperation with Viome is a commitment to medical innovation, not just an investment.
We try our best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
